NEO stock: buy or sell?
January 17th, 2020
NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States.
Should I buy NEO stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best time to buy them. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, 2 buy setups are elegible for NeoGenomics stock now:
|New all-time high||Yes|
|New 52 week high||Yes|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is NeoGenomics stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we gathered 2 ratings published for NEO stock in the last 30 days.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-3-29||Needham & Company LLC||n/a||Buy|
NEO stock analysis
After several days of continuous rises in past weeks, NeoGenomics slipped -1.69% to $32.05.
After climbing to all-time highs several times in past weeks, NeoGenomics slipped -1.69% to $32.05. Since price and SMA200d lines crossed up on October, NEO climbed $11.19 (53.64%). From a daily perspective, NEO is in a short term uptrend after plotting its last bottom ($27.81, on January/3) higher than the previous bottom, and its last top ($33.21, on Wednesday) also over the previous top. Now trading in between its last bottom and last top NEO might consolidate in a plain range, waiting to break out over $33.21 or down under $27.81. On December/17, SMA50d and SMA100d crossed up triggering a rise of 19.63%. On Wednesday, NEO hit a new all time high, pushing higher than on Tuesday tops. Check different trading setups that use ATHs as triggers.
NeoGenomics shares boosted 6.44% this week and topped a new all time high at $33.21.
Since price and SMA40w lines crossed up late October 2019, NEO climbed $12.10 (60.65%). Since SMA10d and SMA20w crossed up by mid December 2019, NEO price climbed $5.63 per share (21.31%).
NEO stock price history
NEO IPO was on March 16th, 2004 at $0.57 per share1. Since then, NEO stock surged a 5,522.80%, with an average of 368.20% per year. If you had invested right after NEO's IPO a $1,000 in NEO stock in 2004, it would worth $55,228.00 today.
1: Adjusted price after possible price splits or reverse-splits.
NEO stock historical price chart
NEO stock reached all-time highs on Wednesday with a price of $33.21.
NEO stock price target is $24.50How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. We detected 2 price predictions for NEO stock published in the last month:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-7-31||Raymond James||Raises Target||$23.00||$27.00||17.4%|
|2019-3-29||Needham & Company LLC||Raises Target||$19.00||$22.00||15.8%|
Financials and fundamental analysis
Earnings date and Earnings per ShareSince February, when NeoGenomics posted its last earnings report, it . Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual turnover report draw an extraordinary gain of 15.19% to $276.74 M USD. When comparing 2018 vs 2017, in contrary, profit margin (that is, the net income divided by revenues) appreciated a 1.12% to 0.95%.
|2013||$66 M||-||$2.03 M3.1%||-|
|2014||$87 M||30.99%||$1.13 M1.3%||-44.24%|
|2015||$100 M||14.62%||$-2.54 M-2.5%||-323.94%|
|2016||$244 M||144.57%||$-5.72 M-2.3%||125.76%|
|2017||$240 M||-1.57%||$-0.40 M-0.2%||-93.08%|
|2018||$277 M||15.19%||$2.64 M1.0%||-766.67%|
Quarterly financial resultsNeoGenomics posted $76.48 million in revenues for 2018-Q4, a 10.68% up compared to previous quarter. Reported quarter earnings marked $0.35 M with a profit margin of 0.46%. Profit margin declined a -2.47% compared to previous quarter when profit margin was 2.93%. When comparing sales to same quarter last year, NeoGenomics sales marked a tragic correction and slightly fell a -4.14%. Looking back to recent quarterly results, NeoGenomics posted 3 negative quarters in a row.
|2017-Q2||$66 M||-||$-0.04 M-0.1%||-|
|2017-Q3||$63 M||-4.60%||$-5.10 M-8.1%||11,760.47%|
|2017-Q4||$80 M||26.54%||$4.10 M5.1%||-180.35%|
|2018-Q1||$63 M||-20.50%||$0.64 M1.0%||-84.29%|
|2018-Q2||$68 M||6.82%||$-0.38 M-0.6%||-159.01%|
|2018-Q3||$69 M||1.99%||$2.02 M2.9%||-632.37%|
|2018-Q4||$76 M||10.68%||$0.35 M0.5%||-82.55%|
|2019-Q1||$96 M||24.98%||$-2.42 M-2.5%||-786.69%|
NeoGenomics ownershipWhen you are planning to invest in shares of a company, it's always worth to check its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For NeoGenomics, 6.08% of all outstanding shares are owned by its staff.
Bearish positions for NEO stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to NeoGenomics:
|Market cap||$3.3 B|
|Total shares||104.4 M|
|Float shares||100.6 M|
|- Institutional holdings (%)||83.7%|
|- Insider holdings (%)||6.1%|
|Shares in short selling||0.0%|
|Friday, January 17th, 2020|
|Day range||$31.82 - $32.90|
|Average true range||$0.96|
|50d mov avg||$27.08|
|100d mov avg||$24.27|
|200d mov avg||$23.56|
NeoGenomics performanceTo better understand NeoGenomics performance you must becnhmark its gains with other related stocks in same sector or industry. We chose as the bechmarking frame for NeoGenomics stock.